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Background: Pharmacokinetic (PK) and pharmacodynamic (PD) data are limited for artesunate (AS) and
amodiaquine (AQ) in uncomplicated Plasmodium falciparum.
Methods: From 2007-8, 54 P. falciparum-infected, Kenyan adults were assigned randomly fixed dose (FD) ASAQ
(n = 26) or non-fixed (NF) ASAQ (n = 28). Total doses were 600 mg AS (both arms) + 1,620 mg (FD) or 1,836 mg
(NF)AQ. Follow-up extended over 28 days. PK data were collected for AS, dihydroartemisinin (DHA), AS + DHA
combined as DHA equivalents (DHAeq), AQ, desethylamodiaquine (DAQ),and their relationships assessed against
the PD collected data consisting of parasitological efficacy, adverse events (AEs), and the Bazett’s corrected
QTinterval (QTcB).
Results: Mean AUC 0-72 of dihydroartemisinin equivalents (DHAeq) when administered as a fixed dose (FD)
compared to NF dose were similar: 24.2 ±4.6 vs 26.4±6.9 μmol*h/L (p = 0.68) Parasite clearance rates were also
similar after 24 hrs: 17/25 (68%) vs 18/28(64.3%) (p = 0.86),as well as at 48 hrs: 25/8 (100%)vs 26 (92.9%)/28 (p = 0.49).
Mean FD vs NF DAQ AUC0-28 were 27.6±3.19 vs 32.7±5.53 mg*h/L (p = 0.0005). Two PCR-proven new infections
occurred on Day (D) 28 for estimated, in vivo, DAQ minimum inhibitory concentrations of 15.2 and 27.5 ng/mL.
Combining the FD and NF arms, the mean QTcB at D2+4 hrs increased significantly (p = 0.0059) vs baseline: 420
vs410 ms (Δ = 9.02 (95% confidence interval 2.72-15.31 ms), explained by falling heart rates, increasing DAQ
concentrations and female sex in a general linear mixed effects model. Ten of 108 (9.26%) AEs (5/arm) reported
by 37/54 (68.5%) patients were possibly or probably drug related. Severe, asymptomatic neutropaenia developed
in 2/47 (4.25%) patients on D28: 574/μL (vsD0: 5,075/μL), and 777/μL (vsD0: 3,778/μL).
Conclusions: Tolerability of both formulations was good. For QTcB, a parameter for ECG modifications, increases
were modest and due to rising DAQ concentrations and falling heart rates as malaria resolved. Rapid parasite
clearance rates and no resistant infections suggest effective pharmacokinetics of both formulations.
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Fixed dose (FD)artesunate-amodiaquine (ASAQ)was
developed, WHO prequalified, and registered by a
consortium coordinated by the Drugs for Neglected Dis-
eases initiative (DNDi)[1,2]. Dosing is straightforward
and based on four optimized, age/weight categories [3]
which provides greater dosing accuracy than coblistered
ASAQ [4] and good adherence [5]. As of 2014, ASAQ is
available for use in 35 countries, including 32 in Africa
[6]. Where tested in Africa, FD ASAQ has consistently
achieved high efficacy, achieving Day 28 cure rates
of ~93, 94 and 100% in children ≤60 months of age from
Burkina Faso [6], Benin [5] and Central African Republic
[10], respectively; ~98% in children <eight years of age
in Cote D’Ivoire, Cameroon and Senegal [7] and <five
years of age in the Democratic Republic of Congo (DRC)
[8], as well as 100% in Nigerian children <12 years of
age [9]. FD ASAQ was non-inferior to artemether-
lumefantrine (AL) in two trials, achieving cure rates ex-
ceeding ~95% and non-inferiority margins of 3% [8,11].
Non-fixed (NF) dose ASAQ has also achieved high cure
rates across Africa [12-26] with some reports of efficacy
<90% in focal parts of DRC, Tanzania, Sierra Leone, and
Rwanda [26-29].
ASAQ is generally well tolerated and, across a range of
studies, has a broadly similar adverse event (AE) profile
as AL [5,9,11,30,31]. However, one study found signifi-
cantly higher rates of fatigue, nausea, vomiting, and
anaemia in the FD ASAQ arm compared to AL [32]. In
this study, the relationship between Day (D)7 desethyla-
modiaquine (DAQ) concentrations and AE varied with
age: a higher median D7 DAQ was associated with
fatigue in children under the age of five, and vomiting in
those aged ≥ five years of age. Rates of early vomiting or
of rejecting the tablets (i.e., spitting them out) were low
(0.2 to 6%) [6,11,32], and more common in children
under five years old [DNDi data on file [11,32]].
In the past, AQ as malaria prophylaxis caused signifi-
cant and sometimes fatal hepatotoxicity, which some-
times occurred with severe neutropaenia [33-35]; AQ is
no longer used as malaria prophylaxis. Increases in liver
enzymes following treatment with ASAQ or AL appear
more likely in chronic hepatitis B carriers and were inde-
pendent of DAQ concentrations [32]. AE rates of all
grades for increased concentrations of aspartate and
alanine aminotransferase (AST and ALT) ranged from 3
to 8% in both FD ASAQ and AL recipients [32]. Grade 3
(>5-20 × upper limit of normal (ULN)) and grade 4
(>×20 ULN) hepatotoxicity was rare and occurred in
only 4/496 (0.8%) of patients aged > five years, not quite
significantly higher (p = 0.06) than in AL-treated patients
1/502 (0.2%) [32], and in 1/529 (0.19%) of children
≤60 months of age from Burkina Faso [6]. Rates of all
grade neutropaenia in patients aged > five years were 19and 21% in 496 FD ASAQ and 502 AL recipients, respect-
ively; corresponding rates in children < five years of age
were lower: 4% (n = 149) and 5.3% (n = 150) [32] respect-
ively. Furthermore, repeated use of ASAQ in 208 malaria-
infected children from Uganda over two years (median
number of treatments = 16) showed a similar AE profile to
205 children who received repeat dose AL (median num-
ber of treatments = 15). The incidence (ASAQ vs AL) of
moderate/severe hepatic dysfunction and severe neutro-
paenia was low in both cohorts: five vs three episodes and
two vs one episode, respectively.
Available cardiac data on AQ and ASAQ are very
limited. Ngousse et al. found clinically insignificant
prolongation of PR, QRS and the Bazett’s corrected QT
interval (QTcB) in Plasmodium falciparum-infected
adults, and no relationship between the QTcB and DAQ
concentrations at 52 hours, the mean time for maximal
DAQ concentrations [36]. Similarly, Adjei et al. failed to
find a positive relationship between DAQ concentrations
and either the D3 QTcB or the D3-D0 change in QTcB
in African children and adolescents [37]. The lack of an
apparent association between QTcB and DAQ concen-
trations suggest a disease effect on the QTcB but does
not exclude definitively a DAQ-related cardiac effect.
Intravenous AQ produced QRS interval prolongation in
six out of seven healthy, Thai adult volunteers, but no
significant changes in heart rate, PR or corrected QT in-
tervals [38]. DAQ was not detected at any time, suggest-
ing AQ caused the slowing of intracardiac conduction.
As part of the development of FD ASAQ, a phase IIb
pharmacokinetic and safety study was conducted to
complement population pharmacokinetic (PK) data from
the phase III trial [39] and to explore PK and pharmaco-
dynamic (PD) relationships.
Methods
Study design and site subject eligibility criteria
The study was an open label, phase IIb, randomized,
controlled trial comparing the safety, population PKs,
and efficacy of FD ASAQ and NF ASAQ. The study was
conducted between November 2007 and June 2008 in
the Chulaimbo Sub-District Hospital in Kisumu, western
Kenya. This area has intense transmission of chloroquine-,
AQ-, and sulphadoxine-pyrimethamine- resistant P.
falciparum [40-42] as well as significant malaria-related
anaemia [43]. In 2007, NF ASAQ had a polymerase chain
reaction (PCR)-corrected failure rate of just under 10% in
children in the same area [44]. The protocol was approved
by the Kenya Medical Research Institute (KEMRI) Ethical
Review Committee. This study was conducted in accord-
ance with the principles of Good Clinical Practice and the
Declaration of Helsinki. Written informed consent was
obtained from patients or an independently witnessed
thumb print, as appropriate.
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Fully informed, consenting patients aged 18 to 60 years
presenting with acute, uncomplicated P. falciparum with
an asexual parasitaemia of >1,000 parasites/μL and
either a history of fever or a measured temperature of
≥37.5°C in the preceding 24 hours were enrolled. Exclu-
sion criteria were (i) mixed Plasmodium infection; (ii)
pregnancy (urine test for human chorionic gonadotropic
hormone (βHCG) or lactation; (iii) clinical and/or la-
boratory features of severe malaria; (iv) severe malnutri-
tion; (v) a concomitant febrile illness of any cause; (vi)
significant known comorbidities e.g., cardiac, renal,
hepatic diseases, HIV/AIDS; (vii) hypersensitivity to AS
or AQ; (viii) an ECG abnormality requiring urgent
treatment; (ix) splenectomy; and, (x) ingestion of an
artemisinin in the previous three days and/or ingestion of
sulphadoxine-pyrimethamine in the previous seven days.Randomization and treatment
Patients were computer randomized to either FD ASAQ
or NF ASAQ before the trial. Treatment regimens were
contained in opaque, sealed envelopes in a locked
cabinet and were opened after randomization to ensure
adequate concealment of drug allocation. Supervised
dosing followed the manufacturer’s recommendations:
(i) FD: two ASAQ tablets/day for three days; one tablet
contains AS 100 mg and AQ 270 mg (sanofi-aventis,
France; batch number 0002, expiry date June 2008) for a
total dose of 600 mg AS and 1,620 mg AQ; (ii) NF: AS
200 mg/day (four tablets of 50 mg Arsumax® (sanofi-
aventis, France; batch number 060504, expiry date May
2008) + AQ 612 mg/day (four tablets 153 mg Flavoquine®
(sanofi-aventis, France; batch number 417, expiry date July
2009) for three days, giving total doses of 600 mg AS and
1,836 mg AQ. Patients were observed for 1 hour after
drug administration. A repeat dose was administered if
there was early vomiting during this time. No concomitant
food was given.Study procedures
At baseline (D0), medical and drug histories were taken,
physical examinations performed, Giemsa stained thick
and thin blood films were made and blood samples
obtained (see below). Thick films were examined and
reported as the number of parasites (N)/200 white blood
cells (WBCs), converted to N/μL by assuming a total
WBC count of 8,000 cells/μL. A negative film was
declared when the examination of 1,000 WBCs did not
reveal any asexual parasites. Basic clinical examinations
were performed and malaria blood film slides prepared
on D1, 2, 3, 7, 14, 21, and 28. Standard 12 lead ECGs
were performed on D0 pre-dose, D0 + 2 hours, D0 +
4 hours, D2 + 2 hours, D2 + 4 hours and D28. Womenunderwent urine pregnancy testing at screening and
on D28.
Blood sampling
Full blood counts and liver function tests were per-
formed on D0 (pre-dose), D7and D28, and repeated as
clinically indicated. Blood samples for drug concentra-
tions were taken from each patient at the following fixed
days: D0 (pre-dose), D7, D14, D21, D28, and also ran-
domly at the following time points: 0.25, 0.50, 1, 1.5, 2,
4 hours post-dosing on D0, and at 0.25, 0.50, 1, 1.5, 2,
4 hours on D2.
Two to three drops of blood were collected on a 3
MM filter paper (Whatman, UK) on D0, D7, D14, D21,
and D28 for genotyping by PCR of three genetic
markers: merozoite surface proteins (msp1 and msp2)
and glutamate rich protein (glurp). Genotyping was done
for patients with recurrent infections (day of recur-
rence). A new infection was diagnosed if any one of the
three alleles at baseline and recurrence was different; a
resistant infection was diagnosed if alleles were shared at
baseline and recurrence [45].
Treatment outcomes
The WHO classification of treatment outcomes was
used [46]. Early treatment failure (ETF) was defined as
(i) the development of danger signs or severe malaria on
D1, 2 or 3 in the presence of parasitaemia; (ii)parasit-
aemia on D2 greater than on D0 irrespective of oral
temperature; and, (iii) parasitaemia on D3 with oral
temperature ≥37.5°C; (iv) parasitaemia on D3 ≥ 25% of the
count on D0. Late clinical failure (LCF) was defined as (i)
development of danger signs or severe malaria after com-
pleting the full course of drug administration (D4-D28) in
the presence of parasitaemia, without meeting ETF criteria
previously; and, (ii) presence of parasitaemia and an oral
temperature ≥37.5°C after completing the full course of
drug administration (D4-D28). Late Parasitological Fail-
ure (LPF) was defined as the presence of parasitaemia
from D7-D28 and an oral temperature <37.5°C without
meeting ETF and LCF criteria previously. Adequate
clinical and parasitological response (ACPR) was defined
as the absence of parasitaemia on D28 irrespective of oral
temperature and not having previously met ETF, LCF or
LPF criteria.
Rescue treatment
Patients who either failed treatment or required alterna-
tive treatment because of an AE were treated with either
oral AL or intravenous quinine, as clinically indicated.
Adverse events
An AE was defined as a new symptom, sign, clinical syn-
drome, or laboratory result that developed or worsened
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4 (mild, moderate, severe, very severe respectively),
according to the National Cancer Institute Toxicity
Table [18]. Locally defined, normal laboratory ranges
were used to grade laboratory AEs. AE drug relation-
ships were determined by the physicians as unrelated,
unlikely, possible, probable, and very probable. A ser-
ious AE was one of the following: (i) life-threatening
event; (ii) death; (iii) hospitalization or prolongation of
hospitalization; (iv) disability or incapacitation; and, (v)
congenital anomaly. The following AEs were sought at each
assessment: headache, weakness, anorexia, nausea, abdom-
inal pain, itching, vomiting, diarrhoea, rhinitis, cough, ver-
tigo, and the presence of a rash. Individual AE frequencies
were modelled with a logistic model with the DAQ
AUC 0–28 (not log-transformed) as covariate. Odds
Ratios and 95% confidence intervals were estimated
for each AE per 1 unit increase in DAQ AUC 0–28.
Statistical analysis
A sample size calculation was not determined but based
on a similar phase IIb study [48,49], a sample size of 25
patients per arm was considered adequate to demon-
strate the disposition of AS, dihydroartemisinin (DHA),
AQ and DAQ of the two formulations and to model the
rate corrected QT intervals. Treatment efficacy was de-
termined with PCR correction of recurrent parasitaemia
and excluded all patients who did not complete follow-
up to D28. The safety analysis included all patients who
had received at least one dose of the study drug. Data
were described as frequencies (proportion), median
(range) or mean (standard deviation). Proportional data
were compared by Chi-squared or Fisher’s exact test, as
appropriate. Wilcoxon rank sum/sign rank (skewed data)
or unpaired/paired ‘t’ tests (normally distributed data)
were used for continuous data (SAS v 19.1.3 software
(SAS Institute, Cary, NC, USA). All tests were two-
tailed and a p value of ≤0.05 was considered statistically
significant.
Pharmacokinetic methods and analysis
Plasma samples were analysed using liquid chromatography-
mass spectrometry/mass spectrometry (LC-MS/MS)
methods developed and validated by SYNEXEL Re-
search International.AQ and DAQ were analysed by
reversed-phase liquid chromatography (X Terra C18
MS −3.5 μm; 50 mm × 3 mm id) and MS/MS (Sciex
API3000) detection in the Turbo Ion Spray positive
mode. AS and DHA and the internal standard (AST-D4)
were analysed by reversed-phase LC-MS/MS in the Turbo
Ion Spray positive mode.
AS/DHA and AQ/DAQ concentration-time data were
analysed by use of the First-Order method with Inter-
action of the non-linear mixed effects modelling programNONMEM (version VI, version 2.0, double precision).
Population PK modelling of AQ/DAQ was reported else-
where [50]. Concentrations below the LOQ were removed
from the database. AS and DHA concentrations were
fitted simultaneously, as it was the case for AQ/DAQ.
Several structural pharmacokinetic models were investi-
gated. Classical one- and two-compartment models with
first order absorption were evaluated for AS and AQ. The
transformations of AS into DHA and of AQ into DAQ
were assumed to be linear processes. One and two com-
partment models were evaluated to describe the dispos-
ition of AS, DHA, AQ and DAQ. Because it was not
identifiable, central distribution volumes of DHA and
DAQ were fixed to 1 L. Several error models (i.e., propor-
tional, exponential, and additive random effects model)
were also investigated as means of describing interpatient
and residual variabilities. Systematic testing for the influ-
ence of continuous covariates on the pharmacokinetic
parameters was done by use of a generalized model, ac-
cording to the following equation, by using, for example,
CL/F and BW:
CL=F ¼ TV CL=Fð Þ  BW
medianBW
 θ
where TV(CL/F) was the typical value of the apparent
clearance for a patient with the median covariate value,
and θ was the influential factor for body weight.
The influence of binary covariate (Dosage Form, sex,
ALAT) was investigated as follows:
CL=F ¼ TV CL=Fð Þ  θ
where θ was equal to the influential factor for Fixed
Dose Combination, Men, ALAT > 30 U/L, and was
otherwise fixed to 1.
The significance of a relationship between a pharma-
cokinetic parameter and a covariate was assessed by use
of the chi-square test of the difference between the ob-
jective functions of the basic model (without the covari-
ate) and the model with the covariate. A covariate was
retained in the model if it produced a minimum de-
crease in the objective function of 3.64 units (P = 0.05, 1
degree of freedom) and if its effect was biologically
plausible. An intermediate multivariate model that in-
cluded all selected covariates was then obtained. A co-
variate was retained in the final multivariate model if its
deletion from the intermediate model led to a 6.63-point
increase in the objective function (P = 0.01, 1 degree of
freedom). At each step, the goodness of fit was evaluated
by use of a graph of the weighted residuals versus time
after administration of the dose (time) or versus the
predicted concentrations.
The accuracy and robustness of the final population
models were assessed by normalized prediction errors
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parameters were used to perform 200 simulations of the
database. The 2.5th and the 97.5th percentiles as well as
the 50th (median) of simulated concentrations were
plotted against observed concentrations.
Individual Bayesian estimates of the PK parameters
were used to calculate individual areas under the curve
(AUC) and elimination half-lives (T½). Individual AUC
values of AS and DHA, expressed in μmol*h/L, were
combined in order to obtain DHA equivalents (DHAeq).
ECG analysis
All ECGs were read and analysed by a clinical research
organization, according to a prospectively designed
analytical plan. ECG intervals were measured using on-
screen callipers, as previously described [49]. The QT
interval was corrected using three correction formulae:
(i) Bazett’s QTcB =QT/RR0.5; (ii) Fridericia’sQTcF =QT/
RR0.33; and, (iii) a new correction for malaria patients:
QTcN =QT/RR0.4 defined in the cited paper [51]. A sep-
arate paper will detail the cardiac findings. Here only the
QTcB is reported. A linear mixed effects model exploredEnrolle
random
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Post dose study 
withdrawals: 
Lost to follow-up n=1 
Completed the study to 
D28 without parasites 
n=24 
Analysed by ITT n=26
Analysed per-protocol 
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Figure 1 Trial profile.the relationships between the QTcB interval over time
with age, sex, treatment, temperature, AQ and DAQ
concentrations, and heart rate taken as fixed factors, and
a random intercept.Role of the sponsor
The study was funded by the DNDi which was involved
in all aspects of the study, e.g., protocol development,
study oversight, data review, and intellectual contribu-
tion to this publication.Results
A total of 54 patients were randomized, 26 to the FD
ASAQ arm and 28 to the NF ASAQ arm. All but one
patient (FD ASAQ arm) completed their treatment,
four patients were lost to follow-up, and there were
two late treatment failures (Figure 1). Patient baseline
characteristics were similar in the two groups with the
exception of the absolute neutrophil and monocyte




Received NF ASAQ 
n = 28 
Completed treatment  
n= 28 
Post dose study 
withdrawals: 
Lost to follow-up n=3 
Late treatment failure 
n=2 
Completed the study to 
D28 without parasites 
n=23 
Analysed by ITT n=28 
Analysed per-protocol 
n=25 
Table 1 Patient characteristics
Characteristic FD ASAQ NF ASAQ P value
N = 26 N = 28
Age 23.1 (17.9-60.1) 24.2 (18.1-56.9) 0.98
Gender (n, M/F) 12/14 13/15 0.98
Luo ethnic group [N(%)] 23 (88.5) 24 (85.7) 1.00
Symptoms [N(%)]
Headache 23 (88.5) 26 (92.9) 0.66
Anorexia 18 (69.2) 14 (50.0) 0.15
Nausea 16 (61.5) 17 (60.7) 0.95
Weakness 13 (50.0) 15 (53.6) 0.79
Vomiting 12 (46.2) 16 (57.1) 0.42
Abdominal pain 10 (38.5) 13 (46.4) 0.55
Diarrhoea 3 (11.5) 6 (21.4) 0.47
Cough 1 (3.8) 4 (14.3) 0.35
Signs (range)
Weight (kg) 58.0 (50.0-90.0) 60.0 (39.0-82.0) 0.78
Temperature (°C) 37.2 (36.0-39.0) 37.2 (35.8-40.0) 0.42
Pulse rate (beats/min) 92.5 (62.0-124.0) 90.5 (57.0-131.0) 0.90
Systolic blood pressure
(mmHg)
119.5 (90.0-157.0) 125.5 (85.0-160.0) 0.48
Diastolic blood pressure
(mmHg)
70.0 (55.0-92.0) 74.0 (51.0-99.0) 0.37
Palpable spleen 0 1/27 (3.7) 1.0









1 (3.8) 0 (0.0) 0.48
Haemoglobin (g/dL) 13.3 (10.3-17.6) 13.2 (9.9-17.7) 0.53
White blood cells
(× 103/μL)
5.6 (5.2-6.8) 5.1 (2.3-9.5) 0.09
Neutrophils (× 103/μL) 3.5 (1.3-5.6) 2.6 (0.8-8.1) 0.02
Lymphocytes (× 103/μL) 1.3 (0.5-2.5) 1.3 (0.5-3.3) 0.22
Monocytes (× 103/μL) 0.8 (0.6-1.1) 0.6 (0.4-0.8) 0.005
Eosinophils (× 103/μL) 0.07 (0.03-0.58) 0.08 (0.05-0.19) 0.60
Platelets (× 103/μL) 96.0 (44.0-229.0) 95.5 (18.0-254.0) 0.86
AST* (IU/L) 28.0 (13.4-82.9) 31.2 (15.1-56.1) 0.99
ALT* (IU/L) 21.6 (10.5-123.1) 23.2 (3.8-105.9) 0.37
Total bilirubin (μmol/L) 12.0 (1.7-50.6) 13.1 (0.0-65.3) 0.74
Creatinine (μmol/L) 70.7 (17.7-113.2) 75.6 (53.0-114.9) 0.26
All continuous data are expressed as median (range).
*AST – aspartate aminotransferase, ALT- alanine aminotransferase.
Table 2 Population estimates of the base and the final
model for AS/DHA
Base model Final model
Parameter Mean Standard error Mean Standard error
KaAS(h
−1) 2.45 0.34 2.41 0.34
CL/FAS (L/h) 797 102 616 98.4
V/FAS(L) 119 51.8 85.2 36.0
FM(%) 0.81 0.16 0.00781 0.00108
Kem (h−1) 0.819 0.266 0.742 0.166
ѲBWkem NA NA 1.65 0.46
ѲFORM NA NA 1.79 0.36
ω2CL/FAS 0.101 0.089 NE NE
ω2V/FAS 1.94 2.23 2.21 2.27
ω2kemDHA 0.000352 0.0666 NE NE
σ2adAS 0.000218 0.000122 0.000277 0.00015
σ2multAS 0.665 0.154 0.674 0.116
σ2adDHA 0.0438 0.0299 0.0324 0.0223
σ2multDHA 0.391 0.093 0.374 0.0726
KaAS: absorption rate constant of AS, CL/FAS: apparent clearance of AS, V/FAS:
apparent distribution volume of AS, FM: fraction of AS metabolized into DHA,
K34 and K43: distribution rate constants of DAQ, Kem: elimination rate constant
of DHA, ѲBWkm: influential factor of BW on DHA kem, ѲFORM : influence of
dosage form on AS bioavailability, ω2CL/FAS: interindividual variability of
CL/FAS, ω
2V/FAS: interindividual variability of V/FAS, σ
2multAS: proportional
residual error for AS, σ2adAS: additive residual error for AS , σ
2multDHA:
proportional residual error for DHA, σ2adDHA: additive residual error for DHA,
NA: Not Available, NE: Not Estimated.
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The mean administered doses of AS (± SD) were similar
(p = 0.56) for both arms: (i) 3.5 ± 0.11 for the FD vs 3.42
± 0.008 mg/kg/d for the NF dose but were significantly
lower for AQ (p = 0.001) in the FD arm: 9.24 ± 0.23 I10.73 ± 0.34 mg/kg/d for an absolute mean and relative
difference of 1.49 (95% CI 0.6-2.34) mg/kg/d and 16.1%
(95% CI 6.8-25.4).
The final AQ model was a one-compartment model
with first-order absorption for AQ and an irreversible
transformation to DAQ; DAQ disposition was character-
ized by a two-compartment model. Body weight was the
only significant covariate to explain the inter-individual
variability of the V/F of AQ and the elimination rate
constant of DAQ [50].
The mean DAQ AUC0–28 values were FD 27.6 ± 3.2 vs
NF 32.7 ± 5.5 mg*h/L (p = 0.0005), a mean difference of
15.6%. This difference became non-significant (p = 0.73)
when the DAQ AUC0–28 was divided by the total dose
of AQ administered in mg: 0.051 ± 0.006 vs 0.053 ±
0.009 mg*h/L/mg AQ. Mean FD and NF half-lives were
similar between the two arms: 204 ± 22 vs 214 ± 37 hours
(p = 0.58), respectively.
The final AS/DHA model was a 1-compartment model
with first-order absorption for AS, and first-order and ir-
reversible transformation into DHA. Disposition of
DHA was characterized by a 1-compartment model with
first-order elimination.
Body weight was found to explain the interindividual
variability of the elimination rate constant of DHA (kem).
However, once this covariate included, the interindividual
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fore removed from the model. Dosage form was found to
influence AS bioavailability. Indeed, the bioavailability of
AS was 79 % higher with the loose form. The values of the
population parameters for AS/DHA for the base and final
model are displayed in Table 2.
Lack of bias of the Final Model was evidenced on the
graphs displaying the normalized prediction errors ver-
sus population predicted concentrations or time after
dose (Figure 2). Goodness of fit and lack of bias was also
evidenced by the Visual Predictive Checks (Figure 3).
Indeed, the AS and DHA observed concentrations were
symmetrically distributed around the median of the
simulated concentrations and 4.9% of the observed
AS concentrations and 7.6% of the observed DHA
concentrations were outside the 95% non-parametric
confidence interval that was built on the simulated
concentrations.
The AUC0–72 values as DHAeq were similar (mean
and standard deviation) between the two forms: 24.2 ±

















Figure 2 Normalized Prediction Errors (npde) versus time after dose (Adverse events
Over 28 days, a total of 37/54 (68.5%) patients reported
a total of 108 AEs: 18/26 (69.2%) FD vs 19/28 (67.9%)
NF (p = 0.9). Ten AEs (five/arm:19.2% FD, 17.9% NF)
were considered to be possibly or probably related to
ASAQ treatment (Table 3). Early vomiting requiring
redosing occurred in one (3.8%) FD recipient and an-
other FD-treated patient developed an aphtous ulcer,
but was not neutropaenic during the study. Absolute
neutrophil counts ranged from 2,618 to 3,526 neutro-
phils/μL blood.
There was no relationship between the DAQ AUC0–28
and the odds of reporting headache, weakness, an-
orexia, nausea, vomiting, abdominal pain, or itching
(Additional file 1).
One NF-treated female had two serious AEs. She was ad-
mitted to hospital for symptomatic recurrent P. falciparum
malaria (40,365 parasites/μL) on D28 and was treated with
AL. She was also thought to have typhoid fever and was





T1, hours), or predicted concentrations (PRED, mg/L).
AB
Figure 3 Visual predictive checks for AS (A) and DHA (B).
DV: Dependent variable = concentration (mg/L); T1: time after dose,
W1: AS, W2: DHA, circles = observed concentrations, solid line: 50th
percentile obtained from the simulated concentrations, lower dotted
line: 2.5th percentile obtained from the simulated concentrations,
upper dotted line: 97.5th percentile obtained from the simulated
concentrations.
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Because the differences in the haematological and bio-
chemical parameters between the arms were not statisti-
cally different, they have been combined (Table 4). Over
time, the mean haemoglobin (Hb) concentration nadired
on D7, rising thereafter, but was significantly lower on
D28 vs. baseline. The mean neutrophil and monocytecounts declined significantly over time whilst the mean
lymphocyte and eosinophil counts increased signifi-
cantly. One patient (NF) had severe neutropaenia of 795
neutrophils/μL at baseline, which rose to 1,200 neutro-
phils/μL by D28. Two out of 47 (4.25% (95% CI: 0.5 to
14.5%)) patients developed severe (grade 3) neutropaenia
on D28: (i) FD: 574/μL (D0: 5,075/μL), and (ii) NF: 777/μL
(D0: 3,778/μL). Both patients were well and afebrile. Six
patients had severe D0 thrombocytopenia (platelets
<50×103/μL) which returned to normal by D7 or D28.
Of the biochemical values, only the mean total bilirubin
declined significantly over time. There were no abnor-
mal AST, ALT or creatinine values throughout the
study.
ECG data
A total of 363 ECGs recorded were analysed. Because
there were no statistically significant differences in the
mean QTcB, median PR and QRS intervals, and mean/
median changes between the two arms at any time point,
the QTcB data were combined for analysis. QRS inter-
vals remained within the normal range at all time points
(Table 5). At D2 + 4 hours, the mean increase in the
QTcB over baseline was 9.02 milliseconds (ms) (95%
confidence intervals: 2.72-15.31 ms (p = 0.0059). The
nonlinear mixed effects modelling identified heart rate
(inverse relationship), DAQ concentrations (positive
relationship) and female sex (positive relationship) as
significant, independent, explanatory variables for the
QTcB over time (Table 6).
Efficacy
There were no ETFs in either arm. Two NF ASAQ-
treated female patients developed symptomatic, new in-
fections on D28 for PCR-corrected ACPR rates of 24/24
FD and 23/23 NF (p = 0.49) patients. Pertinent clinical
and PK data for the two new infections were: (i) Patient
A: D0 parasitaemia: 16,815 parasites/μL, D28 parasit-
aemia: 40,365 parasites/μL, weight 53 kg, AS dose:
3.7 mg/kg/d, AQ dose: 11.5 mg/kg/d, estimated DAQ
AUC0–28 33.23 mg*h/L, estimated DAQ concentrations
were 27.5 ng/mL (D21) and 11.9 ng/mL (D28), and esti-
mated DAQ T½ was 212 hours (8.3 days); (ii) Patient B:
D0 parasitaemia: 20,860 parasites/μL, D28 parasitaemia:
19,228 parasites/μL, weight 44 kg, AS dose: 4.54 mg/kg/d,
AQ dose:13.9 mg/kg/d, estimated AUC0–28 32.77 mg*h/L,
estimated DAQ concentrations were 15.3 ng/mL (D21)
and 9.31 ng/mL (D28), and estimated DAQ T½ 214 hours
(8.9 days).
On D1, persistent parasitaemia was present in 8/25
(32%) FD and 10/28 (35.7%) NF (p = 0.86) patients. No
FD patient had parasites on D2compared to 2/28 (7.1%)
for the NF (p = 0.49) patients. Both patients were apara-
sitaemic on D3. One patient in the FD and none in the
Table 3 Summary of the solicited treatment emergent adverse events (TEAEs) reported at least once by 37 patients
TEAEs (% of patients) Possibly or probably drug-related TEAEs (% of patients)
Description FD ASAQ NF ASAQ All FD ASAQ NF ASAQ All
(N = 26) (N = 28) (N = 54) (N = 26) (N = 28) (N = 54)
At least one TEAE 18 (69.2) 19 (67.9) 37 (68.5) 5 (19.2) 5 (17.9) 10 (18.5)
Headache 10 (38.5) 12 (42.9) 22 (40.7) - - -
Weakness 8 (30.8) 11 (39.3) 19 (35.2) - 2 (7.1) 2 (3.7)
Anorexia 7 (26.9) 7 (25.0) 14 (25.9) 1 (3.8) - 1 (1.9)
Nausea 6 (23.1) 8 (28.6) 14 (25.9) - - -
Abdominal pain 6 (23.1) 7 (25.0) 13 (24.1) 1 (3.8) 1 (3.6) 2 (3.7)
Itching 6 (23.1) 3 (10.7) 9 (16.7) 3 (11.5) 2 (7.1) 5 (9.3)
Vomiting 4 (15.4) 2 (7.1) 6 (11.1) - - -
Diarrhoea 2 (7.7) 2 (7.1) 4 (7.4) - 1 (3.6) 1 (1.9)
Rhinitis 2 (7.7) 2 (7.1) 4 (7.4) 1 (3.8) - 1 (1.9)
Cough 1 (3.8) 2 (7.1) 3 (5.6) - - -
All FD vs NF ASAQ comparisons were not statistically significant.
Ogutu et al. Malaria Journal 2014, 13:498 Page 9 of 13
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FD patient had gametocytes on D14.
Discussion
In this small group of semi-immune Kenyan adults, both
ASAQ formulations were well tolerated, produced mod-
est changes in the ECG and were effective for treating
acute, uncomplicated, P. falciparum. Two patients devel-
oped asymptomatic severe neutropaenia on D28.
The AE profile of both ASAQ formulations was simi-
lar and clinically reported AEs were unrelated to DAQ
exposure; however, there was a trend in the reporting of
fatigue and increased DAQ exposure. In their large
study, Shramm et al. found a positive relationship be-
tween D7 DAQ and the reporting of fatigue in childrenTable 4 Summary of mean (standard deviation) and mean ch
D0 D7 D2
Haematology
Haemoglobin (g/dL) 13.4 (2.1) 12.0 (1.8) 12.6
White blood cells* 5.4 (1.4) 6.3 (1.9) 5.6
Neutrophils* 3.1 (1.4) 2.6 (1.1) 2.2
Lymphocytes* 1.3 (0.6) 2.6 (0.9) 2.4
Monocytes* 0.71 (0.28) 0.66 (0.26) 0.48
Eosinophils* 0.13 (0.16) 0.37 (0.43) 0.41
Platelets*† 96.0 (18–254) 234 (187–311) 175
Biochemistry
AST¶ (U/L) 32.9 (13.2) 33.0 (18.7) 28.3
ALT¶ (U/L) 29.5 (21.8) 33.8 (20.8) 22.0
Total bilirubin‡ 16.9 (14.8) 7.2 (7.9) 7.0
Creatinine‡ 73.5 (20.3) 71.8 (17.6) 71.9
*x 103/μL; ‡μmol/L; †median (range); ¶AST – aspartate aminotransferase; ALT- alanin< five years of age. Itching was reported by ~17% of pa-
tients, a higher rate compared to the <1-3% reported in
paediatric studies [5,9,11,30], and may be related to
adults being better able to express themselves. No pa-
tients needed parenteral rescue treatment for persistent
drug-induced vomiting and only one patient needed to
be redosed. These tolerability data appear more satisfac-
tory than those from young children in whom ~7.5% re-
quired redosing [31] and ~2% required parenteral rescue
treatment for persistent drug-induced vomiting [6,30].
Asymptomatic, severe neutropaenia was found in two
patients (~4%) on D28, both of whom had normal neu-
trophil counts at baseline. Data on the natural dynamics
of neutrophils show that when malaria patients of all
ages are treated with a variety of anti-malarial drugs,anges in haematological and biochemical data
8 Δ p Δ p
D7-D0 D7-D0 D28-D0 D28-D0
(1.8) −1.4 <0.000 −0.8 <0.000
(2.3) 0.9 0.0012 0.3 0.44
(1.5) −0.4 0.046 −0.9 0.00046
(0.9) 1.2 <0.000 1.0 <0.0000
(0.24) −0.05 0.25 −0.22 <0.000
(0.47) 0.24 <0.000 0.28 <0.0000
(140–213) 126.0 <0.000 81.0 <0.0000
(11.0) 1.1 0.68 −4.4 0.0268
(10.2) 5.7 0.03 −8.1 0.005
(6.6) −10.0 <0.000 −9.4 0.00014
(27.4) −2.3 0.50 −3.4 0.48
e aminotransferase.
Table 5 Median (interquartile range) and median changes from baseline of the Bazett’s corrected QT interval, heart
rate, and PR and QRS intervals for both artesunate amodiaquine arms combined*








Δ vs D0 p vs D0
Variable QTcB interval ms Heart rate b/min
D0, pre-dose 410 394 425 92 80 103
D0 + 2 h 412 398 428 2 0.3652 85 74 98 −5 0.0012
D0 + 4 h 416.5 397 429 3.5 0.2593 79 71 89 −8.5 <.0001
D2, pre-dose 411 388 423 −4.5 0.2551 59 53 64 −35 <.0001
D2 + 2 h 415 393 433.5 3 0.4897 59.5 54 64.5 −36 <.0001
D2 + 4 h 420 400 431 7.5† 0.0059 59 55 65 −31.5 <.0001
D28 398 384 418 −10.5 0.0016 66 59 74 −25 <.0001
Variable QRS interval ms PR interval ms
D0, pre-dose 78 72 88 151.5 140.5 172.5
D0 + 2 h 82 72 89 2 0.2572 158 146 176 5 0.0061
D0 + 4 h 82 76 88 1.5 0.1122 161 153 175 10 <.0001
D2, pre-dose 84 74 96 2.5 0.0084 163 154 185 12 <.0001
D2 + 2 h 85 79 95.5 6 0.0001 167 155.5 184.5 13.5 <.0001
D2 + 4 h 86 78 95 5 0.0003 172 151 187 15 <.0001
D28 86 76 92 5.5 0.0073 164 147 179 12 <.0001
*Only the QTcB data are normally distributed but the median interquartile ranges are shown for all parameters for clarity.
†Corresponding mean 95% confidence intervals are: 9.02 (2.72-15.31) ms.
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whilst lymphocytes increase post-treatment [52]. Rates
of post-treatment neutropaenia of all grades were similar
between ASAQ (13%), other ACT (14%) and monother-
apy (15%), and the risk of developing neutropaenia was
inversely related to age. The rate of severe (grade 3/4)
neutropaenia for all drugs combined was 3% with no sig-
nificant difference between ASAQ and other anti-
malarial drugs [52]. These data, therefore, do not suggest
ASAQ recipients are at a higher risk of developing neu-
tropaenia of any grade compared to other antimalarial
drugs. Adjei et al. demonstrate an almost identical de-
cline in the mean neutrophil counts over 28 days be-
tween NF ASAQ and AL in malaria patients aged up to
14 years [30]. Post- treatment severe neutropaenia isTable 6 Final random effects model summarizing the significa
QTcB interval over time




Sex F 20.8761 4.6
Sex M 0 .
ECG heart rate 0.1461 0.0
DAQ concentrations 0.02972 0.0usually asymptomatic or mildly symptomatic and can
last for up to four weeks [11,30].
There was a small but statistically significant increase
in the mean QTcB interval of ~9 ms (upper 95%, CI
15 ms), four hours after the last dose of ASAQ, repre-
senting a maximum increase of <4% over baseline. This
time point corresponds to the mean maximum DAQ
concentration and when malaria is resolved/resolving.
Indeed, increasing DAQ concentrations and decreasing
heart rate were significant explanatory factors along with
female sex. The positive relationship between DAQ and
QTcB contrasts with the findings of Ngousse et al. and
Adjei et al. who analysed their data by simple correlation
- an analysis that may have lacked sensitivity[36,37]. The
QTcB increases observed in the treated patients arent, independent factors to explain the changes in the
ndard error DF t Value Pr > |t|
613 52 39.85 <0.0001
0421 296 −3.8 0.0002
15 296 1.93 0.0543
453 296 4.49 <0.0001
. . .
6916 296 2.11 0.0355
1026 296 2.9 0.0041
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http://www.malariajournal.com/content/13/1/498consistent with other malaria studies [49,53-56] and
suggest FD ASAQ is cardiac safe at therapeutic doses.
The AS, DHA, AQ, and DAQ population PK-modelled
data [50] were consistent with other published studies
[39,57-59]. AS bioavailability when administered as a FD
was less compared to the NF [50] but DHAeqs were
similar. Interestingly, this is consistent with FD AS mef-
loquine in Thai adults [48] but contrasts with children
aged <60 months from Burkina Faso who had similar AS
bio-availabilities with the same FD and NF ASAQ for-
mulations used in this study [39]. AS is essentially a
prodrug for DHA and both share similar parasiticidal
properties. DHAeq is probably a better PK marker, so a
reduction in the bioavailability of AS exposure per se is
of little clinical importance in the initial parasiticidal
effect, as shown in the patients who had rapid falls in para-
site counts in both arms, consistent with ASAQ-treated
children from Burkina Faso [6]. The mean administered
AQ dose and consequently the DAQ AUC0–28 were signifi-
cantly lower (~16% lower) in the FD arm compared to the
NF arm. FD ASAQ was designed for dosing simplicity
across four age/weight bands. The good efficacy record of
FD ASAQ across most of Africa supports the use of this
simplified dosing regimen [5-7,9,11].
The NF arm had two, symptomatic, new infections on
D28, representing a failure of post-treatment prophylaxis
in an area of intense transmission of CQ and AQ re-
sistant malaria [44]. P. falciparum parasites become
visible by light microscopy after an interval of at least
six days following sporozoite innoculation. The in vivo
minimum inhibitory concentrations (MICs) of DAQ
for the falciparum parasites in these two patients
approximates the D21 DAQ concentrations, estimated
at ~15 and ~28 ng/mL. These values are equivalent
to ~45 and ~85 nmol/mL and are below and above
one definition (≥60 nmol/mL) of in vitro DAQ resist-
ance [60], suggesting at least one new infection could
be DAQ resistant.
Phase IIb studies involve low numbers of patients
which limits the ability to detect small differences of
given parameters. Nevertheless, the distinct properties
in the PK characteristics of the two formulations
studied and the key factors affecting the modest in-
crease in QTcB at the time of maximum DAQ concen-
trations were demonstrated.Conclusion
This phase II study in adults has demonstrated the
cardiac safety of ASAQ at therapeutic doses and similar
PK characteristics of AS and DHA. FD ASAQ is a good
option where AQ resistance is low or where national
malaria control programmes wish to switch from effica-
cious NF ASAQ to FD ASAQ.Additional file
Additional file 1: Odds ratio estimates, with Wald 95% confidence
intervals, for reporting certain symptoms as adverse events per one
unit increase in the desethyl amodiaquine AUC0–28.
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